依普利酮治疗高血压的效果怎么样呢？

It is a new type of selective aldosterone receptor antagonist. It was approved for clinical use by the State Food and Drug Administration in 2002. The pure product is white or off-white crystal. It has stronger aldosterone antagonism than spironolactone and has extremely low affinity for androgen and progesterone receptors. It has few adverse reactions. It has definite efficacy in the treatment of hypertension, heart failure and myocardial infarction. It has fewer adverse reactions and good tolerance. It is a good alternative drug to spironolactone.

How effective is eplerenone in treating high blood pressure? 

For severe hypertension that cannot be controlled by a combination of multiple antihypertensive drugs, the addition of eplerenone can significantly reduce blood pressure, especially the decrease in systolic blood pressure is more significant. Combined treatment with angiotensin-converting enzyme inhibitors (ACEI) and beta-blockers can improve the quality of life and reduce mortality in patients with severe heart failure and myocardial infarction. The combined use of treatment for heart failure after acute myocardial infarction and standard treatment drugs can reduce the total mortality in the treatment group by 15% (P=0.008).

Eplerenone and enalapril are equally effective in reversing left ventricular hypertrophy and hypertension, with less coughing side effects, and the combined effect is more obvious; there are few adverse reactions, except for the adverse reactions of increased blood potassium, other adverse reactions are no different from the placebo group, and there are almost no sex hormone-related side effects of spironolactone.

The FDA (U.S. Food and Drug Administration) has approved eplerenone for use in stable patients with left ventricular systolic dysfunction (ejection fraction <40%) and congestive heart failure after acute myocardial infarction (MI) to improve survival rates. Eplerenone is the first aldosterone receptor blocker approved for this indication. The FDA's approval was based on the results of the EPHESUS (Eplerenone Efficacy and Survival Study in Heart Failure After Acute Myocardial Infarction) trial. In patients with heart failure after myocardial infarction, eplerenone plus standard care reduced mortality by 15% compared with placebo and standard care (ACE inhibitors and beta-blockers).

Common dosage for adults with congestive heart failure: Initial dose: 25 mg, orally, once a day; and within 4 weeks, gradually increase to the target dose, as tolerated by the patient, to a target dose of 50 mg, orally, once a day.

Common dosages for adult hypertension: It can be used alone or in combination with other antihypertensive drugs. Initial dose: 50 mg, orally, once a day. Maintenance dose: 50 mg, orally, 1-2 times a day. Maximum dose: 100 mg/day. Obvious antihypertensive effect will appear within four weeks of medication. Patients whose blood pressure does not respond adequately to the initial dose can be increased to 50 mg, twice a day.